Department of Orthopaedic Surgery and Rheumatology, Kamagaya General Hospital, Chiba, Japan.
Department of Orthopaedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Mod Rheumatol Case Rep. 2023 Jun 19;7(2):350-353. doi: 10.1093/mrcr/rxad021.
Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA). Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis. Herein, we described the case of an 87-year-old woman treated with Janus kinase inhibitor (JAKi). Chest computed tomography revealed increased honeycombing; she was administered nintedanib while continuing RA treatment. The combination treatment (JAKi and nintedanib) controlled the RA disease activity without ILD deterioration. This case shows the potential of combination treatment with JAKi and nintedanib for the prevention of worsening of disease activity in RA and ILD.
间质性肺病（ILD）是类风湿关节炎（RA）常见的关节外表现。尼达尼布已被批准用于治疗特发性肺纤维化。本文描述了一例接受 Janus 激酶抑制剂（JAKi）治疗的 87 岁女性病例。胸部计算机断层扫描显示蜂窝状影增加；在继续 RA 治疗的同时，给予尼达尼布。联合治疗（JAKi 和尼达尼布）控制了 RA 疾病活动，ILD 无恶化。该病例表明，JAKi 和尼达尼布联合治疗可能预防 RA 和 ILD 疾病活动恶化。
